H And Q Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -6.00%
(FY 2023)
- Profit 100.38%
(FY 2023)
- Ebitda -360.14%
(FY 2023)
- Net Worth 116.17%
(FY 2023)
- Total Assets 62.27%
(FY 2023)
About H And Q Pharma
The Corporate was formerly known as H And Q Pharma (Opc) Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bharat Jonnala and Nagoor Basha serve as directors at the Company.
- CIN/LLPIN
U24299TG2020PTC141506
- Company No.
141506
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jul 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does H And Q Pharma Private Limited offer?
H And Q Pharma Private Limited offers a wide range of products and services, including Cleaning Liquids & Wipes, Disinfectant Spray, Hand Sanitizers & Personal Hygiene, Hand Sanitizer & Disinfectant, Diagnostic Medical Imaging Equipment, Ultrasound Accessories, Industrial Chemicals & Supplies, Disinfectant Chemicals, Floor Cleaner.
Who are the key members and board of directors at H And Q Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bharat Jonnala  | Director | 22-May-2023 | Current |
| Nagoor Basha | Director | 08-Jul-2020 | Current |
Financial Performance of H And Q Pharma.
H And Q Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6% decrease. The company also saw a substantial improvement in profitability, with a 100.38% increase in profit. The company's net worth Soared by an impressive increase of 116.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of H And Q Pharma?
Unlock access to H And Q Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at H And Q Pharma?
Unlock and access historical data on people associated with H And Q Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of H And Q Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped H And Q Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED.webp){kind=small}
